Mode
Text Size
Log in / Sign up

Meta-analysis links higher BMI to increased early-onset colorectal cancer risk

Meta-analysis links higher BMI to increased early-onset colorectal cancer risk
Photo by Stephen Phillips - Hostreviews.co.uk / Unsplash
Key Takeaway
Consider higher BMI as an associated risk factor for early-onset colorectal cancer in younger adults.

This systematic review and meta-analysis examined the association between body mass index (BMI) measured prior to diagnosis and the risk of early-onset colorectal cancer (EOCRC), defined as diagnosis before age 50. The analysis pooled data from 11 cohort studies, though specific study settings and follow-up durations were not reported. The comparator was normal weight.

The main finding was that overweight/obesity (BMI ≥25 kg/m²) was significantly associated with a higher risk of EOCRC, with an odds ratio (OR) of 1.59 (95% confidence interval [CI]: 1.25-1.93). When analyzed separately, overweight (OR=1.24, 95% CI: 1.07-1.40) and obesity (OR=1.81, 95% CI: 1.08-2.55) both showed increased risk, with a stronger association for obesity. A sensitivity analysis using an age cutoff of ≤55 years confirmed the robustness of the results (OR=1.63). Subgroup analyses suggested the association was greater in men (OR=1.50) than in women (OR=1.16, though the result for women was not fully reported), and regional variations were observed, with the strongest associations found in North America and Europe.

Safety and tolerability data were not reported. Key limitations of the evidence were not detailed in the provided input, but inherent limitations of meta-analyses of observational studies apply, including potential residual confounding and heterogeneity between included cohorts. The funding sources and author conflicts of interest were also not reported. For practice, these findings from observational data highlight a consistent association between higher BMI and EOCRC risk, reinforcing weight management as a potential public health strategy. However, clinicians should interpret the association cautiously and avoid implying direct causation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: The incidence of early-onset colorectal cancer (EOCRC; ≤50 years) has been increasing globally. High BMI is a recognized predisposing factor for colorectal cancer, but its contribution to EOCRC is not yet fully understood. We conducted an updated systematic review and meta-analysis of cohort studies to clarify the association between BMI and EOCRC risk. Following PRISMA guidelines, PubMed, EMBASE, Scopus, Science Direct, and Web of Science were searched through August 2025. Eligible studies reported BMI measured prior to diagnosis and EOCRC outcomes. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using random-effects models. Subgroup analyses by sex, region, and age cut-offs were performed. RESULTS: Eleven cohort studies were included. In the primary analysis (EOCRC defined as <50 years), compared with normal weight, overweight/obesity (combined as BMI ≥25 kg/m) was significantly associated with higher EOCRC risk (OR = 1.59, 95%CI: 1.25-1.93). Stratified analyses showed a modest increase with overweight (OR = 1.24, 95%CI: 1.07-1.40) and a stronger association with obesity (OR = 1.81, 95%CI: 1.08-2.55). Sensitivity analyses using ≤55 years as the cutoff confirmed robustness of results (OR = 1.63). Sex-specific analyses indicated greater risk among men (OR = 1.50) than women (OR = 1.16). Regional variations were observed, with the strongest associations in North America and Europe. CONCLUSIONS: Our findings indicated that elevated BMI could be associated with increased risk of EOCRC, particularly among obese individuals and men. These findings highlight obesity as a modifiable risk factor and underscore the importance of weight management strategies in younger populations to mitigate the rising global burden of EOCRC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.